Healthcare / BiotechnologyTokyo
$60.00
+2.00 (+3.45%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 18%
FCF escenarios
weak_data · normalized FCF $-989.9M · quality 43.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
5/100
F
Piotroski
1/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$2.7B
P/E
N/A
•EV/EBITDA
N/A
•ROE
-130.6%
↓Gross Margin
-412646.8%
↓Debt/Equity
N/A
•TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-33.5%
FCF CAGR
—
FCF margin
-442012.4%
FCF / Net income
0.73x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $314000.0 · net income $-1.91B · FCF $-1.39B
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $314000.00 | $314000.00 | $6.1M | $530000.00 | $1.1M |
| Net Income | $-1.91B | $-1.91B | $-889.1M | $-933.4M | $-1.17B |
| EBITDA | $-1.61B | $-1.61B | $-859.2M | $-950.5M | $-1.16B |
| EPS | — | — | -31.98 | -39.63 | -61.04 |
| Gross Margin | -412646.8% | -412646.8% | -8741.3% | -128356.0% | -85406.6% |
| Operating Margin | -525053.5% | -525053.5% | -14717.8% | -187567.4% | -109566.0% |
| Net Margin | -608766.6% | -608766.6% | -14511.0% | -176116.2% | -109888.9% |
| Balance Sheet | |||||
| Current Ratio | 4.34 | 4.34 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-1.39B | $-1.39B | $-537.6M | $-989.9M | $-1.07B |
| Returns | |||||
| ROE | -130.6% | -130.6% | -34.9% | -40.6% | -43.5% |
| Valuation | |||||
| P/B | 1.66 | 1.66 | 1.47 | 1.35 | 1.07 |
| Growth & Yield | |||||
| Revenue Growth | -94.9% | -94.9% | 1056.0% | -50.3% | — |
| EPS Growth | — | — | 19.3% | 35.1% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-44.4%
Start / end P/E
n/dx → n/dx
EPS bridge
-31.98 → n/d
Residual
-44.4%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.